Skip to content

Released Aug 12, 2025, after the close

10-Q filed Aug 12, 2025, 43 days after period end · 0000950170-25-107309

Q2 2025 · 10-Q
Revenue$1.91M−71.8% vs Q2 2024+17.1% vs Q1 2025
Net Income-$34.07MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.29N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$36,968,000N/M
Operating Cash Flowderived-$24,587,000N/M
Free Cash Flowderived-$25,949,000N/M
Margins · derived
Operating margin-1938.5%−1272.8 pt vs Q2 2024
Net margin-1786.6%−1219.1 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$1.91M$6.77M$933.00K$18.55M
Net Income-$34.07M-$38.43M-$52.76M-$76.11M
EPS Diluted-$0.29-$0.33-$0.54-$0.79

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR